Story · Medicine & Biotech
Stopping GLP-1 treatment could double risk of heart attack, stroke, or death, study finds
5 outlets · first reported by The BMJ 2d ago · latest 1d ago · 25 hours of coverage · 3 countries
Coverage, in order
-
2d agoStopping GLP-1 treatment could double risk of heart attack, stroke, or death, study finds
Stopping a GLP-1 treatment was linked to twice the combined risk of heart attack, stroke, or death for some people with type 2 diabetes, a study finds.Previous research indicated that glucagon-like peptide (GLP-1) receptor agonists can reduce heart attacks, strokes, and death in people with type 2…
-
1d agoFor diabetes patients, stopping GLP-1 drugs linked to doubled risk of heart attack, stroke, death
People with type 2 diabetes who stopped GLP-1 treatment had twice the risk of heart attack, stroke or death than those who continued, according to a new study.
-
1d agoRe: Stopping GLP-1 treatment could double risk of heart attack, stroke, or death, study finds
Agreement: I Agree Body: Dear Editor GLP-1 discontinuation: treatment cessation is not treatment failure The association between GLP-1 receptor agonist discontinuation and increased cardiovascular events is concerning, although the interpretation deserves closer scrutiny. The difference in…
-
1d ago
Interromper o uso de Ozempic pode dobrar o risco de infarto, alerta estudoInterromper o tratamento com Ozempic pode ocasionar reganho de peso
-
1d ago
Stopping GLP-1s associated with increased risk of heart attack and stroke, study findsStopping GLP-1 treatment is associated with a substantially increased risk of heart attack, stroke or death, a new study has found. While GLP-1 drugs reduce cardiovascular risk in some patient groups, an international team of researchers found that discontinuing treatment may increase the risk of…
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.